MODIFIED PRIMERS FOR LOOP-MEDIATED ISOTHERMAL AMPLIFICATION AND USE THEREOF
20230295705 · 2023-09-21
Assignee
Inventors
Cpc classification
C12Q2525/186
CHEMISTRY; METALLURGY
C12Q2525/161
CHEMISTRY; METALLURGY
C12Q2525/186
CHEMISTRY; METALLURGY
International classification
Abstract
The present invention relates to an inner primer which includes, in the 3′-end direction, a blocker for inhibiting gene amplification and an RNA sequence that is complementary to a template target nucleic acid sequence and is cleaved by a ribonuclease; a primer composition and a kit including the same; and a method for detecting a target nucleic acid sequence by using the same. The present invention can increase amplification efficiency and detection specificity by inhibiting non-specific binding during an amplification process.
Claims
1. An inner primer modified for looped-mediated isothermal amplification (LAMP) of a target nucleic acid sequence, wherein the inner primer is a forward inner primer (FIP), a backward inner primer (BIP), or a combination thereof, wherein the FIP, the BIP, or the combination thereof includes an RNA sequence that is complementary to a template target nucleic acid sequence in a 3′-end direction and cleaved by Ribonuclease (RNase) and a blocker that inhibits gene amplification.
2. The inner primer for the LAMP of claim 1, wherein the RNA sequence cleaved by the RNase includes a reporter in a 5′-end direction.
3. The inner primer for the LAMP of claim 1, wherein the forward inner primer (FIP), the backward inner primer (BIP), or the combination thereof includes a DNA sequence that is complementary to the template target nucleic acid sequence in the 3′-end direction and recognized by the RNase.
4. A primer composition for looped-mediated isothermal amplification (LAMP), comprising: the inner primer for the LAMP of claim 1; and a forward outer primer (F3) and a backward outer primer (B3).
5. A kit for looped-mediated isothermal amplification (LAMP) comprising the composition of claim 4.
6. A method for detecting a target nucleic acid sequence, the method comprising: (a) selecting a sequence of six regions of B3, B2, B1, F1c, F2c, and F3c or a sequence of six regions of F3, F2, F1, B1c, B2c, and B3c from 5′ to 3′-end direction of the target nucleic acid sequence; and (b) performing Looped-mediated isothermal amplification (LAMP) on a sample using the primer composition of claim 4 and a Ribonuclease (RNase).
Description
DETAILED DESCRIPTION OF THE EMBODIMENT
[0019] The present invention provides a modified inner primer for the looped-mediated isothermal amplification (LAMP) of a target nucleic acid sequence, in which the inner primer may be a forward inner primer (FIP) or a backward inner primer (BIP) or a combination thereof, and the FIP, the BIP or the combination thereof includes a blocker which inhibits gene amplification and an RNA sequence which is complementary to a template target nucleic acid sequence in a 3′-end direction and is cleaved by Ribonuclease (RNase).
[0020] The term “amplification” as used herein refers to an increase in the number of copies of a nucleic acid molecule, such as a gene or a fragment of a gene. The amplified product may also be referred to as an amplification product. An example of in vitro amplification may include polymerase chain reaction (PCR) in which a sample (e.g., a biological sample) is brought into contact with a pair of oligonucleotide primers under conditions that permit hybridization of the primer to a nucleic acid molecule in the sample. Further, other examples of in vitro amplification may include real-time PCR, quantitative real-time PCR, reverse transcription PCR (RT-PCR), quantitative RT-PCR (qRT-PCR), looped-mediated isothermal amplification (LAMP); reverse-transcription LAMP (RT-LAMP); strand displacement amplification (SDA) (U.S. Pat. No. 5,744,311; and the like).
[0021] The term “Looped-mediated isothermal amplification (LAMP)” is a method capable of performing an amplification reaction under a condition of isothermal temperature, unlike the existing polymerase chain reaction (PCR). While the conventional PCR should be accompanied by a temperature change through three steps of denaturation, annealing, and extension, the looped-mediated isothermal amplification is a molecular biological technique that enables annealing and extension at a constant temperature without such a temperature change to replicate and amplify a desired portion of a target sequence. Since the isothermal amplification reaction uses Bst DNA polymerase, etc. having a strand displacement function instead of Taq DNA polymerase used in conventional PCR, annealing and extension are performed at a fixed temperature close to the Tm value without depending on heat. Therefore, unlike PCR, the isothermal amplification reaction can amplify genes without specialized equipment and has the advantage of being able to amplify genes at high concentrations within a short time.
[0022] In general, the LAMP method uses four or more primers specific for the six regions in the target nucleic acid sequence. The primers include a forward outer primer (F3), a backward outer primer (B3), a forward inner primer (FIP), and a backward inner primer (BIP). The four primers are primers used in the LAMP method (Notomi et al., Nucl. Acids. Res. 28:E63, 2000; Nagamine et al., Mol. Cell. Probes 16:223-229, 2002; Mori et al., J. Biochem. Biophys. Methods 59: 145-157, 2004), which is well known to those skilled in the art. Also, in order to increase amplification efficiency or reaction rate, a forward loop primer (Loop F: LF) and a backward loop primer (Loop B: LB) may be further included. The external primers serve to release the DNA double strand during the non-cyclic step of the reaction. The inner primer is composed of nucleic acids corresponding to the forward and backward base sequences so as to form a loop that is essential for looped-mediated isothermal amplification. Additional loop primers attach to the base sequence to which the inner primer does not bind to accelerate the looped-mediated isothermal amplification reaction.
[0023] The four primers are designed to have a sequence corresponding to the sequence of six regions, i.e., a B3 region, a B2 region, a B1 region, an F1c region, an F2c region, or an F3c region on the target nucleic acid, or to have a sequence corresponding to the sequence of an F3 region, an F2 region, an F1 region, a B1c region, a B2c region, and a Bic region. The six regions may be located on a single-stranded target nucleic acid in the order of [B3]-[B2]-[B1]-target region-[F1c]-[F2c]-[F3c] from 5′ to 3′-end direction, or [F3]-[F2]-[F1]-target region-[B1c]-[B2c]-[B3c] from 5′ to 3′ end direction. The four primers may be used to amplify a target nucleic acid sequence including [B3]-[B2]-[B1]-target region-[Flc]-[F2c]-[F3c] from a 5′ to 3′-end direction or [F3]-[F2]-[F1]-target region-[B1c]-[B2c]-[B3c] from a 5′ to 3′-end direction. The four primers may be used to amplify a target region.
[0024] Here, F1, F1c, F2, F2c, F3, F3c, B1, B1c, B2, B2c, B3, and B3c may refer to or describe a specific region on a target nucleic acid, a sequence of the specific region, the primer itself, or a sequence of the primer, and the lower case “c” refers to a complementary sequence. For example, F3 includes a sequence that can anneal to the sequence of the F3c region having a sequence complementary to that of the F3 region, B3 includes a sequence that can anneal to the sequence of the B3c region having a sequence complementary to that of the B3 region, FIP includes an F1c sequence that can anneal to the sequence of the F1 region from 5′ to 3′ end direction and an F2 sequence that can anneal to the sequence of the F2c region, and BIP includes a B1c sequence that can anneal to the sequence of the B1 region from 5′ to 3′ end direction and a B2 sequence that can anneal to the B2c sequence. The LAMP reaction produces DNA having a stem and loop structure with an inverted repeat of the target nucleic acid sequence.
[0025] The target nucleic acid, the target nucleic acid sequence, the target gene, the target gene sequence, or the target sequence refers to a nucleic acid sequence of interest for detection or quantification. The nucleic acid sequence may include a single strand as well as a double strand sequence. The nucleic acid sequence may include a sequence newly generated in the reaction as well as a sequence initially present in a nucleic acid sample.
[0026] The target nucleic acid may include any DNA (gDNA and cDNA), RNA, or a hybrid thereof (chimeric nucleic acid). The target nucleic acid may have a double-stranded or single-stranded form.
[0027] The target nucleic acid may include any natural prokaryotic nucleic acid, eukaryotic nucleic acid (e.g., protozoan and parasites, fungi, yeast, higher plants, lower and higher animals including mammals and humans), virus (e.g., herpes virus, HIV, influenza virus, Epstein-Barr virus, hepatitis virus, polio virus, etc.) nucleic acid, or viroid nucleic acid. In addition, the nucleic acid molecule may be any nucleic acid molecule that is recombinantly produced or may be produced, or that is chemically synthesized or may be synthesized. Thus, nucleic acid molecules may be found or not found in nature. Here, the target nucleic acid sequence may include a known or unknown sequence.
[0028] The term “primer” refers to a short nucleic acid sequence that can be base-paired with a complementary template with a nucleic acid sequence having a short free 3′-end hydroxyl group and serves as a starting point for copying the template strand. The primer may be annealed to the complementary target nucleic acid strand by nucleic acid hybridization and extended along the target nucleic acid strand by a DNA polymerase. The length and sequence of the primers are combined to initiate repeated superposition synthesis of the gene to be amplified, which can be appropriately adjusted according to the ionic strength and maintenance conditions at isothermal temperature, as well as the complexity of the desired DNA or RNA target. The primer may be, for example, 10 to 60, 15 to 60, 15 to 50, 15 to 45, 15 to 40, 20 to 40, 20 to 50, 25 to 50, 25 to 60, or 30 to 60 bp.
[0029] The primer may be chemically synthesized using a phosphoramidite solid support method or other well-known methods. Such nucleic acid sequences may also be modified using a number of means known in the art. Non-limiting examples of such modifications include methylation, capsulation, substitution of natural nucleotides into one or more homologues, and modifications between nucleotides, such as modifications to uncharged linkages (e.g., methylphosphonate, phosphotriester, phosphoroamidate, carbamate, etc.) or charged linkages (e.g., phosphorothioate, phosphorodithioate, etc.). The nucleic acid may be one that contains one or more additional covalently linked residues, such as a protein (e.g., nuclease, toxin, antibody, signal peptide, poly-L-lysine, etc.), intercalating agent (e.g., acridine, psoralen, etc.), chelating agent (e.g., metal, radioactive metal, iron, oxidizable metal, etc.), or alkylating agent. In addition, the primer may be modified by using a marker which may directly or indirectly provide a detectable signal. Examples of the marker include radioactive isotopes, fluorescent molecules, biotin, and the like.
[0030] The term “complementary sequence” as used herein refers to a nucleic acid sequence in which bases of single-stranded nucleic acids form a matching base pair to stably form a double-stranded structure. Such a complementary sequence may be included in the complementary sequence if some matching of the base sequence, e.g., 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 79%, 78%, 77%, 76%, or 75%, as well as 100% matching base sequences can stably form a double-stranded structure.
[0031] The term “annealing” refers to a process in which a single-stranded DNA or RNA molecule having a complementary base sequence forms a stable double-stranded nucleic acid molecule by hydrogen bonding between base pairs.
[0032] The FIP, BIP, or a combination thereof includes an RNA sequence that is complementary to a template target nucleic acid sequence in the 3′-end direction and is cleaved by a Ribonuclease (RNase) and a blocker that inhibits gene amplification.
[0033] The RNA sequence induces DNA-RNA binding cleavage or degradation of RNase. The RNA sequence may be a sequence at a position where looped-mediated isothermal amplification is maintained and possible even if it is removed by RNase. The RNA sequence cleaved by the RNase is complementary to the template target nucleic acid and may be 1 to 20, 1 to 15, 1 to 10, 2 to 8, or 2 to 6 bp, but is not limited thereto.
[0034] The RNase may be RNase H, RNase A, or RNase R1, for example, RNase H. RNase H refers to an RNase that specifically degrades only the RNA strand of a hybrid double strand of RNA and DNA.
[0035] The blocker inhibits DNA polymerization or amplification of a target sequence, and may be an abasic spacer in which a base cannot be aligned. The blocker may be a non-base ribonucleic acid spacer (rSpacer, rSp), a non-base nucleic acid spacer (dSpacer), a C3 spacer, or a C6 spacer that does not include a base, or may be any spacer modification that does not include a base. Alternatively, the blocker may be a mismatch sequence. The mismatch sequence may be adenine, guanine, cytosine, thymine, uridine, or modified therefrom, which is not complementary to the target nucleic acid.
[0036] The blocker may include a quencher.
[0037] The RNA sequence cleaved by the RNase may include a reporter in a 5′-end direction. The reporter refers to selectable markers for notifying the presence, location, or level of a target.
[0038] The reporter may be located in the direction of the 5′ end of the RNA sequence cleaved by RNase, or may be located between 1 to 100, 2 to 85, 5 to 75, 10 to 60, 15 to 50, or 20 to 30 bp in the direction of the 5′ end of the RNA sequence cleaved by RNase, but may not be limited thereto. The reporter may be located in any region of FIP, BIP, or a combination thereof, or any region of F2, B3, or a combination thereof, but is not limited thereto.
[0039] When the RNA strand is degraded or cleaved in DNA-RNA binding, unquenching may be induced as the sequence including the quencher falls off the template DNA. The reporter and the quencher may be donors and acceptors.
[0040] The reporter and quencher may include any molecule known in the art. For example, the reporter and quencher molecules may be selected from the group consisting of Cy2™(506), YO-PRO™-1(509), YOYO™-1(509), Calcein(517), FITC(518), FluorX™(519), Alexa™(520), Rhodamine 110(520), Oregon Green™ 500(522), Oregon Green™ 488(524), RiboGreen™(525), Rhodamine Green™(527), Rhodamine 123(529), Magnesium Green™(531), Calcium Green™(533), TO-PRO™-1(533), TOTO1(533), JOE(548), BODIPY530/550(550), Dil(565), BODIPY TMR(568), BODIPY558/568(568), BODIPY564/570(570), Cy3™(570), Alexa™ 546(570), TRITC(572), Magnesium Orange™(575), Phycoerythrin R&B(575), Rhodamine Phalloidin(575), Calcium Orange™(576), Pyronin Y(580), Rhodamine B(580), TAMRA(582), Rhodamine Red™(590), Cy3.5™(596), ROX(608), Calcium Crimson™(615), Alexa™ 594(615), Texas Red(615), Nile Red(628), YO-PRO™-3(631), YOYO™-3(631), R-phycocyanin(642), C-Phycocyanin(648), TO-PRO™-3(660), TOTO3(660), DiD DilC(5)(665), Cy5™(670), Thiadicarbocyanine(671), Cy5.5(694), HEX(556), TET(536), Biosearch Blue(447), CAL Fluor Gold 540(544), CAL Fluor Orange 560(559), CAL Fluor Red 590(591), CAL Fluor Red 610(610), CAL Fluor Red 635(637), FAM(520), Fluorescein(520), Fluorescein-C3(520), Pulsar 650(566), Quasar 570(667), Quasar 670(705), Quasar 705(610), DABCYL, and BHQ (Black Hole Quencher). For example, the reporter may be FAM, TET, HEX, TAMRA, ROX, Texas Red, Cy3, or Cy5 as a dye, and the quencher may be TAMRA, DABCYL, BHQ 1, or BHQ 2. Multiplex target sequence amplification is possible according to the reporter and quencher molecules.
[0041] The reporter or quencher may modify a sequence to an internal dT or internal dG, an internal dC, an internal dA, an internal dU, or an internal dR (e.g., modify thymine to internal dT), and place the reporter or quencher at the site. In this case, the entire or partial sequence forms a double strand at a temperature equal to or lower than a certain temperature. [0042] Internal dT: Internal Amino-C6(or C2)-deoxythymine [0043] Internal dA: Internal Amino-C6-deoxyadenocine [0044] Internal dC: Internal Amino-C6-deoxycytidine [0045] Internal dG: Internal Amino-C6-deoxyguanosine [0046] Internal dU: Internal Amino-C6-deoxyuridine [0047] Internal dR: Internal Amino-C6-deoxyribose
[0048] The FIP, the BIP, or a combination thereof may include a DNA sequence that is complementary to the template target nucleic acid sequence in the 3′-end direction and recognized by the RNase. The DNA sequence increases the recognition efficiency of RNase. The DNA sequence recognized by the RNase is complementary to the template target nucleic acid and may be 1 to 20, 1 to 15, 1 to 10, 2 to 8, or 3 to 6 bp, but is not limited thereto.
[0049] The primer(s) according to the present invention may be referred to as a High specific isothermal amplification technology (HSIA) primer.
[0050] The present invention also provides a primer composition for the looped-mediated isothermal amplification (LAMP) including an inner primer for the LAMP, a forward outer primer (F3), and a backward outer primer (B3). The F3 and B3 may be template target nucleic acids and those designed according to the above descriptions. The composition may include Ribonuclease (RNase).
[0051] The present invention also provides a kit for the looped-mediated isothermal amplification (LAMP) including the composition.
[0052] The kit may further include a DNA polymerase in the case of the LAMP reaction or a reverse transcriptase and a DNA polymerase in the case of the RT-LAMP reaction. The LAMP may be a LAMP reaction when the template nucleic acid is a DNA molecule or an RT-LAMP reaction when the template nucleic acid is an RNA molecule. The DNA polymerase used in the LAMP reaction or the RT-LAMP reaction is not limited as long as it can be used in the LAMP. The DNA polymerase that can be used in the LAMP or RT-LAMP reaction may be a DNA polymerase having a high strand displacement activity, for example, a DNA polymerase long fragment (LF) of thermophilic bacteria such as Bacillus stearothermophilus (Bst), Bacillus Smithii (Bsm), Geobacillus sp. M (GspM), or Thermodesulfatator indicus (Tin), or a variant thereof, or a Tag DNA polymerase variant. The reverse transcriptase used in the RT-LAMP reaction is not limited as long as it can be used for the RT-LAMP. For example, the reverse transcriptase may be derived from Avian myeloblastosis virus (AMV) or moloney murine leukemia virus (MMLV).
[0053] The kit may further include additional reagents such as a solution including ATP, CTP, GTP, and UTP, a solution including dNTPs, and/or a reaction buffer for a transcription reaction. The kit may include salts, preservatives, enzymes, and the like commonly used for target sequence amplification. The additional reagents may be contained in the same container together with the primer composition, or may be contained separately in a separate container.
[0054] The present invention also provides a method for detecting a target nucleic acid sequence, the method including the steps of: (a) selecting a sequence of six regions of B3, B2, B1, F1c, F2c, and F3c or a sequence of six regions of F3, F2, F1, B1c, B2c, and B3c from 5′ to 3′ end direction of the target nucleic acid sequence; and (b) performing the looped-mediated isothermal amplification (LAMP) on a sample using the primer composition and a Ribonuclease (RNase).
[0055] The sequences of the six regions of B3, B2, B1, F1c, F2c, and F3c, the nucleic acid sequences of the six regions of F3, F2, F1, B1c, B2c, and B3c, and the primer composition are the same as described above.
[0056] The looped-mediated isothermal amplification may be performed in a buffer or reaction solution at 40 to 80 degrees, to 75 degrees, or 55 to 70 degrees, for 1 to 120 minutes, 2 to 90 minutes, 3 to 75 minutes, 4 to 60 minutes, 5 to 40 minutes, 7 to 30 minutes, 8 to 20 minutes, or 8 to 15 minutes. For example, the fluorescence may be measured at 50 to 60 degrees or 52 to 57 degrees for annealing and extension for 1 to 10 minutes or 2 to 7 minutes, at 65 to 75 degrees or 67 to 72 degrees for 1 to 10 minutes or 2 to 7 minutes to activate an enzyme inactivated by an antibody, etc., and at 55 to 65 degrees or 57 to 62 degrees for 20 to 40 minutes or 25 to 35 minutes.
[0057] When the RNase is extended and amplified by a DNA polymerase after RNA is cleaved, and additionally, when the amount of luminescence or fluorescence is measured by unquenching, non-specific binding and dimer formation are suppressed in an amplification process, thereby increasing amplification efficiency and detection specificity.
[0058] The sample may be obtained from a subject such as a human or an animal other than human. The sample may include cells, tissues, or fluids, and may include, but is not limited to, viruses, bacteria, tissues, cells, blood, serum, plasma, lymph, urine, feces, eye fluids, saliva, sputum, semen, brain extracts, spinal cord fluid, appendix, bronchoalveolar lavage fluid, spleen and tonsillar tissue extracts, amniotic fluid, ascites, hair roots, and non-biological samples (e.g., food, water, and soil). Also, the sample may include a natural nucleic acid molecule and a synthetic nucleic acid molecule isolated from a biological source.
[0059] According to the method, the presence and level of a target nucleic acid may be identified by isothermally amplifying the target nucleic acid, and thus disease diagnosis and prognosis prediction such as infectious diseases, and genetic diseases, treatment reactivity, drug resistance, drug tolerance, and the like may be identified.
[0060] Hereinafter, the present invention will be described in detail through embodiments. However, the following embodiments are only for illustrating the present invention, and the contents of the present invention are not limited by the following embodiments.
Example 1. Confirmation of Specificity Improvement when Using Primer Including RNA Sequence and Blocker in Looped-Mediated Isothermal Amplification (LAMP) Using Fluorescence Measuring Real-Time Gene Amplification Device and Intercalating Dye
[0061] In order to solve a problem in which a non-specific signal is generated due to the formation of a primer dimer in a conventional LAMP, it was confirmed whether detection specificity is improved when a HSIA primer including a blocker and an RNA sequence complementary to a template nucleic acid is used.
[0062] Targets and primers were designed with the sequence of the N gene site using the sequence of the SARS-CoV-2 sequence (GenebankID: NC_045512.2).
TABLE-US-00001 TABLE 1 Primer SEQ ID NO. SEQ ID NO: 5′ .fwdarw. 3′ N_F3 primer SEQ ID NO: 1 TGGCTACTACCGAAGAGCT N_B3 primer SEQ ID NO: 2 TGCAGCATTGTTAGCAGGAT N_FIP primer SEQ ID NO: 3 TCTGGCCCAGTTCCTAGGTAGT GACGAATTCGTGGTGGTGA N_BIP primer SEQ ID NO: 4 AGACGGCATCATATGGGTTGCA CGGGTGCCAATGTGATCT N_LF primer SEQ ID NO: 5 GAAATACCATCTTGGACTGAGA TC N_LB primer SEQ ID NO: 6 TGAGGGAGCCTTGAATACAC
[0063] Modified HSIA primers were designed for the N_FIP and N_BIP primers. At the 3′ end of N_FIP (SEQ ID NO: 3) and N_BIP (SEQ ID NO: 4), RNA sequence 3 bp complementary to the SARS-CoV-2 sequence was added, and complementary DNA sequence 4 bp was added so that the blocker was removed by RNase H when the target gene was present. In order to prevent primer dimer formation in the added sequence, a C3 blocker was added to the 3′ end of N_FIP and N_BIP to design primers of N_FIP_HSIA (SEQ ID NO: 7) and N_BIP_HSIA (SEQ ID NO: 8).
TABLE-US-00002 TABLE 2 SEQ ID NO: 5′ .fwdarw. 3′ (r mark corresponds to Primer SEQ ID NO. RNA sequence) N_FIP_HSIA SEQ ID NO: 7 TCTGGCCCAGTTCCTAGGTAGTGA primer CGAATTCGTGGTGGTGArCrGrGT AAA-C3 N_BIP_HSIA SEQ ID NO: 8 AGACGGCATCATATGGGTTGCACG primer GGTGCCAATGTGATCTrUrUrUGG TG-C3
[0064] In order to confirm the difference between the positive amplification signal and the non-specific amplification signal in the real-time gene amplification device when the HSIA primer was not applied, 1.6 μM of each of 1× isothermal amplification buffer 2 (NEB, USA), 0.1% v/v Tween 20, 8 mM MgSO.sub.4, and 1.4 mM of each of dNTP, BST 3.0 polymerase 5U (NEB, USA), and SYBR green 1× (Biorad, USA), and FIP and BIP primers (SEQ ID NOs: 3 and 4) to which the HSIA primer was not applied, 0.2 μM of each of F3 and B3 primers (SEQ ID NOs: 1 and 2), and 0.4 μM of each of LF and LB primers (SEQ ID NOs: 5 and 6) were used.
[0065] The positive amplification signal was confirmed by using an Accuplex™ SARS-CoV-2 reference/standard material (Seracare, USA) at a concentration of 1×10.sup.{circumflex over ( )}5 copies/rxn and adding Diethylpyrocarbonate(DEPC)-treated distilled water (DEPC-treated DW) (Geneall, Korea) as a negative control group to confirm an amplification signal by a dimer. For the nucleic acid amplification conditions, after treatment by ABI7500 real-time PCR (Thermofisher, USA) equipment for 5 minutes at 55° C. and 5 minutes at 70° C., the fluorescence was measured at 60° C. for 30 minutes.
[0066] In order to confirm the specificity improvement effect when HSIA primer was applied, 1.6 μM of each of 1× isothermal amplification buffer 2 (NEB, USA), 0.1% v/v Tween 20, 8 mM MgSO.sub.4, and 1.4 mM of each of dNTP, BST 3.0 polymerase 5U (NEB, USA), and SYBR green 1× (Biorad, USA), and FIP and BIP HSIA primers (SEQ ID NOs: 7 and 8), 0.2 μM of each of F3 and B3 primers (SEQ ID NOs: 1 and 2), 0.4 μM of each of LF and LB primer (SEQ ID NOs: 5 and 6) were used.
[0067] In order to confirm a blocker removal effect in the presence of a target nucleic acid by RNase H, two conditions, i.e., a condition using 6 ng/ml Hot start RNase H (1drop, Korea) and a condition not using the same, were tested. The positive signal was confirmed by using an Accuplex™ SARS-CoV-2 reference/standard material (Seracare, USA) at a concentration of 1×10.sup.{circumflex over ( )}5 copies/rxn, and adding Diethylpyrocarbonate(DEPC)-treated distilled water (DEPC-treated DW) (Geneall, Korea) as a negative control group to confirm an amplification signal by a dimer. For the nucleic acid amplification conditions, after treatment by ABI7500 real-time PCR (Thermofisher, USA) equipment for 5 minutes at 55° C. and 5 minutes at 70° C., the fluorescence was measured at 60° C. for 30 minutes.
[0068]
Example 2. Confirmation of Specificity Improvement when HSIA Primer Including Fluorescent Reporter, RNA Sequence, and Blocker is Used in Multiple Looped-Mediated Isothermal Amplification (LAMP) Using Fluorescence Measurement Real-Time Gene Amplification Equipment
[0069] In a method of amplifying a multiple-looped-mediated gene that amplifies two or more target genes, an individual gene amplification signal was confirmed by using only HSIA primer without a separate probe, and it was confirmed whether non-specific amplification by primer dimer was improved when using HSIA primer during multi-gene amplification.
[0070] The primers used were designed into sequences of N gene (SEQ ID NOs: 1, 2, 3, 4, 5, and 6) and RdRP gene (SEQ ID NOs: 9, 10, 11, 12, 13, and 14) sites using the sequence of SARS-CoV-2 sequence (GenebankID: NC_045512.2).
TABLE-US-00003 TABLE 3 Primer SEQ ID NO. SEQ ID NO: 5′ .fwdarw. 3′ RdRP_F3 primer SEQ ID NO: 9 CCACTAGAGGAGCTACTGTA RdRP_B3 primer SEQ ID NO: 10 TGACAAGCTACAACACGT RdRP_FIP SEQ ID NO: 11 AGGTGAGGGTTTTCTACATC primer ACTATATTGGAACAAGCAAA TTCTATGG RdRP_BIP SEQ ID NO: 12 ATGGGTTGGGATTATCCTAA primer ATGTGTGCGAGCAAGAACAA GTG RdRP_LF primer SEQ ID NO: 13 CAGTTTTTAACATGTTGTGC CAACC RdRP_LB primer SEQ ID NO: 14 GAGCCATGCCTAACATGCT
[0071] The HSIA primers were designed for the N_FIP, N_BIP, RdRP_FIP, and RdRP_BIP primers. In order to confirm the fluorescence signal of each gene, thymine was designed to be an internal dT and then HEX dye was attached to the F2 sequence site of the N_FIP and N_BIP primer sequences. In addition, thymine was designed to be an internal dT and then Texas Red dye was attached to the F2 sequence site of the RdRP_FIP and RdRP_BIP primer sequences. At the 3′ end of each primer, 3 bp of RNA sequence complementary to the SARS-CoV-2 sequence was added, and 4 bp of complementary DNA sequence was added so that the blocker was removed by RNase H when the target gene was present. Primers N_FIP_HSIA_dye, N_BIP_HSIA_dye, RdRP_FIP_HSIA_dye, and RdRP_BIP_HSIA_dye were designed with BHQ added at the 3′ end to prevent primer dimer formation and to quench fluorescent dyes in the added sequence.
TABLE-US-00004 TABLE 4 SEQ ID NO: 5′ .fwdarw. 3′ Primer SEQ ID NO. (r mark corresponds to RNA sequence) N_FIP_HSIA_dye SEQ ID NO: 15 TCTGGCCCAGTTCCTAGGTAGTGACGAAT (internal primer dT HEX) CGTGGTGGTGA rCrGrG TAAA-BHQ1 N_BIP_HSIA_dye SEQ ID NO: 16 AGACGGCATCATATGGGTTGCACGGG (internal dT primer HEX) GCCAATGTGATCT rUrUrU GGTG-BHQ2 RdRP_FIP_HSIA_dye SEQ ID NO: 17 AGGTGAGGGTTTTCTACATCACTATAT (internal primer dT Texas Red) GGAACAAGCAAATTCTATGG rUrGrG TTGG-BHQ1 RdRP_BIP_HSIA_dye SEQ ID NO: 18 ATGGGTTGGGATTATCCTAAATGTG (internal dT primer Texas Red) GCGAGCAAGAACAAGTG rArGrG CCAT-BHQ2
[0072] 1× isothermal amplification buffer 2 (NEB, USA), 0.1% v/v Tween 20, 8 mM MgSO.sub.4, and 1.4 mM of each of dNTP, BST 3.0 polymerase 5U (NEB, USA), and SYBR green 1× (Biorad, USA) were used in common for each test. In order to confirm the performance of the conditions to which the HSIA primer was not applied, the N gene and RdRP primer combinations (SEQ ID NOs: 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13 and 14) were used as 1.6 μM of FIP and BIP primers for each gene, 0.2 μM of F3 and B3 primers, and 0.4 μM of LF and LB primers, respectively.
[0073] In order to confirm the performance of the conditions to which the HSIA primer was applied, HSIA_dye primer combinations (SEQ ID NOs: 1, 2, 5, 6, 9, 10, 13, 14, 15, 16, 17 and 18) of N gene and RdRP were used as 1.6 μM of FIP and BIP primers for each gene, respectively, 0.2 μM of F3 and B3 primers, respectively, and 0.4 μM of LF and LB primers, respectively. In order to confirm whether the HSIA primer can remove the blocker and generate the fluorescence signal by RNase H in the multiple gene amplification, two conditions of non-addition and addition of RNase H were performed under the condition to which the HSIA primer was applied.
[0074] The positive signal was confirmed by using an Accuplex™ SARS-CoV-2 reference material (Seracare, USA) at a concentration of 1×10.sup.{circumflex over ( )}5 copies/rxn, and DEPC-treated distilled water (Geneall, Korea) was added to the negative control group to confirm an amplification signal by a dimer. For the nucleic acid amplification conditions, after treatment by ABI7500 real-time PCR (Thermofisher, USA) equipment for 5 minutes at 55° C. and 5 minutes at 70° C., the fluorescence of FAM, HEX, and Texas Red channels was measured every 1 minute at 60° C. for 30 minutes.
[0075] Since SYBR green, which is an intercalating dye, binds double-stranded DNA, the amount of gene amplification by primer dimers can be confirmed in a positive standard material and a negative control group (DW) according to HSIA application by confirming the FAM fluorescence results obtained by measuring the amount of SYBR green.
[0076]
[0077] In
Example 3. Confirmation of Specificity Improvement when Primer Including Blocker and RNA Sequence is Used in Looped-Mediated Isothermal Amplification (LAMP) Using Absorbance Measuring Isothermal Gene Amplification Equipment
[0078] In absorbance measuring equipment, a primer dimer was formed, and it was examined whether specificity was improved when a HSIA primer using a primer including an RNA sequence and a blocker was applied to a primer sequence generated by a non-specific signal.
[0079] The primer used was designed as the sequence of the N gene site using the sequence of the SARS-CoV-2 sequence (GenebankID: NC_045512.2) (SEQ ID NOs: 1, 2, 3, 4, 5, and 6).
[0080] The HSIA primers were designed for the N_FIP and N_BIP primers. At the 3′ end of N_FIP (SEQ ID NO: 3) and N_BIP (SEQ ID NO: 4), RNA sequence 3 bp complementary to the SARS-CoV-2 sequence was added, and complementary DNA sequence 4 bp was added so that the blocker was removed by RNase H when the target gene was present. In order to prevent dimer formation of the primer in the added sequence, a C3 blocker was added to the 3′ end of N_FIP and N_BIP to design N_FIP_HSIA (SEQ ID NO: 7) and N_BIP_HSIA (SEQ ID NO: 8) primers.
[0081] When the HSIA primer was not applied, dNTP of each of 1 mM Tris-HCL, 10 mM (NH4).sub.2SO.sub.4, 8 mM MgSO.sub.4, 10 mM KCl, 0.1% v/v Tween 20, Cresol Red 16 mM, and 1.4 mM was used to confirm a difference between a positive amplification signal and a non-specific amplification signal in a real-time gene amplification device, and a combination of N gene and RdRP primer (SEQ ID NOs: 1, 2, 3, 4, 5, and 6) was used as 1.6 μM of FIP and BIP for each gene, 0.2 μM of F3 and B3, 0.4 μM of LF and LB, respectively, to confirm performance of a condition to which the HSIA primer was not applied. In order to confirm the performance of the conditions to which the HSIA primer was applied, a combination of N gene and RdRP HSIA primers (SEQ ID NOs: 1, 2, 5, 6, 7, and 8) was used as 1.6 μM of FIP and BIP for each gene, 0.2 μM of F3 and B3, and 0.4 μM of LF and LB, respectively. In order to confirm whether the HSIA primer can remove the blocker and generate the fluorescence signal by Hot start RNase H (1drop, Korea) in the multiple gene amplification, two conditions of non-addition of RNase H and addition of RNase H were performed under the condition of applying the HSIA primer.
[0082] The positive signal was confirmed by using an Accuplex™ SARS-CoV-2 reference material (Seracare, USA) at a concentration of 1×10.sup.{circumflex over ( )}5 copies/rxn, and DEPC-treated distilled water (Geneall, Korea) was added to the negative control group to confirm an amplification signal by a dimer. For nucleic acid amplification conditions, after treatment with 1POT (1drop, Korea) equipment for 5 minutes at 55° C. and 5 minutes at 70° C., absorbance was measured at 60° C. for 30 minutes at a unit of 1 minute.
[0083]